2 weeks Ago By ABMN Staff
Legal & General Group Plc lowered its position in shares of Merus ( NASDAQ:MRUS – Free Report ) by 1.0% during the fourth quarter, HoldingsChannel.com reports.
The fund owned 42,758 shares of the biotechnology company’s stock after selling 419 shares during the quarter. Legal & General Group Plc’s holdings in Merus were worth $1,798,000 at the end of the most recent quarter. A number of other large investors have also recently bought and sold shares of MRUS.
Wells Fargo & Company MN lifted its stake in shares of Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 300 shares during the period.
Avior Wealth Management LLC bought a new stake in Merus in the fourth quarter worth approximately $76,000. MML Investors Services LLC acquired a new position in Merus in the third quarter valued at approximately $206,000. HighTower Advisors LLC lifted its stake in Merus by 10.
9% in the fourth quarter. HighTower Advisors LLC now owns 8,020 shares of the biotechnology company’s stock valued at $337,000 after buying an additional 789 shares during the period. Finally, Raymond James Financial Inc.
bought a new position in shares of Merus during the 4th quarter worth approximately $347,000. 96.14% of the stock is currently owned by institutional investors and hedge funds.
Merus Stock Down 1.8 % Merus stock opened at $43.57 on Friday.
The business has a 50-day simple moving average of $44.05 and a two-hundred day simple moving average of $44.85.
Merus has a 52-week low of $33.19 and a 52-week high of $61.61.
The company has a market cap of $3.01 billion, a P/E ratio of -11.03 and a beta of 1.
02. Analyst Ratings Changes Several analysts have recently weighed in on the stock. Bank of America lowered their price objective on shares of Merus from $73.
00 to $70.00 and set a “buy” rating for the company in a research note on Monday, March 10th. Needham & Company LLC reiterated a “buy” rating and set a $83.
00 price objective on shares of Merus in a report on Wednesday, April 9th. Wells Fargo & Company assumed coverage on shares of Merus in a research report on Friday, February 7th. They set an “overweight” rating and a $91.
00 price objective on the stock. Guggenheim reaffirmed a “buy” rating and issued a $109.00 target price on shares of Merus in a research report on Friday, March 28th.
Finally, Piper Sandler assumed coverage on Merus in a research note on Thursday, February 13th. They set an “overweight” rating and a $84.00 price target on the stock.
One equities research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $85.
31. View Our Latest Analysis on MRUS Merus Profile ( Free Report ) Merus N.V.
, a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. Further Reading Want to see what other hedge funds are holding MRUS? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Merus ( NASDAQ:MRUS – Free Report ). Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter .
.
